-
公开(公告)号:US20220162531A1
公开(公告)日:2022-05-26
申请号:US17671353
申请日:2022-02-14
IPC分类号: C12M1/26 , B03C1/30 , B03C1/01 , B03C1/28 , A61M1/36 , B01L3/00 , C12M3/00 , C12M1/00 , C12M1/12
摘要: A magnetic particle separation system includes a magnetic field generating device having an upper surface with a receiving area formed thereon; and a magnetic field generating element disposed beneath the upper surface, the magnetic field generating element being configured to produce a magnetic field above the upper surface. A container assembly is disposed on the upper surface and includes: a flexible container having an outer wall with an interior surface that at least partially bounds an internal compartment, the outer wall having a front side and an opposing back side with the internal compartment disposed therebetween; a fluid inlet extending through the outer wall at the front side; a fluid outlet extending through the outer wall at the front side; and a first partition projecting into the internal compartment from the front side between the fluid inlet and the fluid outlet.
-
公开(公告)号:US20160304829A1
公开(公告)日:2016-10-20
申请号:US15151587
申请日:2016-05-11
申请人: LIFE TECHNOLOGIES AS
发明人: Axl NEURAUTER , Lars Norderhaug , Ole Brekke , Pål Songe
CPC分类号: G01N33/82 , C12M23/20 , C12M47/02 , C12N13/00 , C40B50/14 , G01N33/543 , G01N33/54326
摘要: Methods of reversal of the binding between a biotin compound and a biotin-binding compound are disclosed. A method of reversibly releasing a biotinylated moiety from a streptavidin (or avidin) coated support is shown as an example. The strong interaction between streptavidin or avidin-biotin is made much weaker by using a combination of modified streptavidin or avidin and modified biotin like desthiobiotin or a derivative thereof like DSB-X Biotin. A protein, such as an antibody may be biotinylated with the modified biotin. When this protein is isolated by binding the modified biotin to the modified streptavidin or avidin bound to an solid surface, it may be released under very gently and very rapid conditions by addition of free biotin. In contrast to proteins obtained by the prior art release methods the protein obtained using the previously available release methods, the proteins obtained using the methods disclosed herein will maintain their native conformation. Uses of the methods in various procedures including cell detachment procedures and techniques of detection, identification, determination, purification, separation and/or isolation of target proteins or nucleic acid molecules are also described.
摘要翻译: 公开了生物素化合物与生物素结合化合物之间的结合的逆转方法。 示出了从链霉抗生物素蛋白(或抗生物素蛋白)包被的载体中可逆释放生物素化部分的方法。 通过使用经修饰的链霉亲和素或抗生物素蛋白和修饰的生物素如脱硫生物素或其衍生物如DSB-X生物素的组合,链霉抗生物素蛋白或抗生物素蛋白 - 生物素之间的强相互作用变得非常弱。 蛋白质,例如抗体可以用修饰的生物素生物素化。 当通过将修饰的生物素结合到与固体表面结合的经修饰的链霉抗生物素蛋白或抗生物素蛋白来分离该蛋白质时,其可以通过添加游离生物素在非常温和和非常快速的条件下释放。 与通过现有技术释放方法获得的蛋白质相比,使用先前可获得的释放方法获得的蛋白质,使用本文公开的方法获得的蛋白质将保持其天然构象。 还描述了在各种方法中使用方法,包括细胞分离程序以及靶蛋白或核酸分子的检测,鉴定,测定,纯化,分离和/或分离技术。
-
公开(公告)号:US20150175698A1
公开(公告)日:2015-06-25
申请号:US14402463
申请日:2013-03-06
申请人: LIFE TECHNOLOGIES AS
发明人: Karoline Schjetne , Tanja Aarvak , Lars Norderhaug
IPC分类号: C07K16/28 , C12N5/0783
CPC分类号: C07K16/2803 , C07K16/00 , C07K16/2809 , C07K16/2896 , C07K2317/53 , C07K2317/55 , C12N5/0636
摘要: Provided are methods and composition useful in isolating or otherwise preparing a population of target cells. In part, it relates to recombinant antibodies comprising an exogenous proteolytic cleavage site and nucleic acid molecules encoding the antibodies.
摘要翻译: 提供了可用于分离或以其它方式制备靶细胞群体的方法和组合物。 其部分涉及包含外源蛋白水解切割位点和编码抗体的核酸分子的重组抗体。
-
公开(公告)号:US20170313772A1
公开(公告)日:2017-11-02
申请号:US15433181
申请日:2017-02-15
发明人: Karoline Schjetne , Tanja Aarvak , Lars Norderhaug
IPC分类号: C07K16/28 , C07K16/00 , C12N5/0783
CPC分类号: C07K16/2803 , C07K16/00 , C07K16/2809 , C07K16/2896 , C07K2317/53 , C07K2317/55 , C12N5/0636
摘要: Provided are methods and composition useful in isolating or otherwise preparing a population of target cells. In part, it relates to recombinant antibodies comprising an exogenous proteolytic cleavage site and nucleic acid molecules encoding the antibodies.
-
-
-